OKUROnKure Therapeutics, Inc.同业对比
OnKure Therapeutics, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OKUR本股 | $116M#8 | — | 0.7x#1 | — | — | -13.0%#9 | — | -34.6%#5 | — | — | 20.9%#4 | — |
| UNCY | $133M#2 | — | 2.5x#7 | 196.8x#5 | -29.0%#6 | 27.7%#5 | -4372.9%#6 | -49.8%#8 | — | — | 20.8%#5 | — |
| APMD | $1.1B#1 | — | — | — | — | — | — | — | — | — | — | — |
| HURA | $129M#3 | — | 7.0x#12 | — | — | -34.8%#10 | — | -167.6%#12 | -0.1%#1 | — | -17.9%#9 | — |
| BMEA | $126M#4 | — | 10.4x#14 | — | — | 55.4%#4 | — | -509.2%#14 | — | — | -14.3%#8 | — |
| MNOV | $123M#5 | — | 3.3x#8 | 300.4x#6 | — | 8.6%#7 | -3242.5%#4 | 32.2%#1 | — | — | 102.4%#3 | — |
| INO | $119M#6 | — | 27.2x#15 | 1819.7x#7 | -70.0%#7 | 20.6%#6 | -132871.3%#7 | -1944.6%#15 | -243.9%#2 | — | -49.5%#11 | — |
| EQ | $118M#7 | — | 2.1x#4 | 2.9x#2 | 13.9%#4 | -177.6%#13 | -57.5%#2 | -40.0%#6 | -368.9%#3 | — | 14.1%#7 | — |
| AARD | $113M#9 | — | 1.5x#3 | — | — | -179.7%#14 | — | -77.0%#9 | — | — | -49.8%#12 | — |
| PMN | $112M#10 | — | 2.3x#5 | — | — | -1529.3%#15 | — | -80.4%#10 | — | — | 17.1%#6 | — |
| MIST | $111M#11 | — | 6.1x#10 | — | — | -51.9%#12 | — | -0.3%#2 | — | — | -54.2%#13 | — |
| GNLX | $107M#12 | — | 6.6x#11 | 13347.4x#8 | 0.0%#5 | -7.6%#8 | -415175.0%#8 | -199.5%#13 | -424.2%#4 | — | — | — |
| COYA | $106M#13 | — | 2.4x#6 | 13.3x#3 | 123.6%#1 | -42.6%#11 | -283.9%#3 | -49.0%#7 | — | — | -20.5%#10 | — |
| CPIX | $104M#14 | — | 6.0x#9 | 2.3x#1 | 17.6%#3 | 56.2%#3 | -6.3%#1 | -16.3%#4 | — | — | 105.2%#2 | — |
| PLYX | $101M#15 | — | 9.3x#13 | — | — | 70.4%#2 | — | -82.1%#11 | — | — | — | — |
| RLYB | $89M#16 | 3.4x#1 | 0.9x#2 | 104.0x#4 | 34.9%#2 | 84.5%#1 | -3853.6%#5 | -9.5%#3 | — | — | 250.0%#1 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议